Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
"2009 was a great year for Hospira," said Christopher B. Begley, chairman and chief executive officer. "We advanced our key businesses, we improved Hospira's financial profile and we fueled profitable growth for our future. In 2010, we continue to execute our strategy and advance innovative solutions to help our customers and patients address their pressing needs. Through Project Fuel, our optimization initiative, we are transforming Hospira, driving towards top-ranking financial performance and increased shareholder value."
During the annual meeting, shareholders:
A full description of the above matters was included in Hospira's proxy statement related to the meeting. The proxy statement is available on Hospira's Web site at www.hospirainvestor.com, as are Mr. Begley's remarks.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.
-- elected the following directors: Connie R. Curran, R.N., Ed.D. Heino von Prondzynski, and Mark F. Wheeler, M.D., M.P.H. all Class III directors whose terms expire in 2013; and -- ratified the appointment of Deloitte & Touche LLP as Hospira's auditors for 2010.
SOURCE Hospira, Inc.
You May Also Like